英国TwistDx 
孟山都和TWISTDX公司将合作进行核酸诊断试剂盒开发，这将提高全球转基因作物的移交转让效率。两家公司采用的是TwistDx的重组聚合酶扩增(RPA)专利技术。与其它DNA检测技术相比，这种技术具有更高的专一性和敏感性，能更快的得到结果。

TwistDx公司CEO Niall Armes 说：“由于这种基于RPA的测试系统速度更快，结果更准确，并且不需要对操作人员进行特别培训，所以它将会是DNA诊断技术的一个进步。我相信它最终会在医药、生物安全及农业等前沿领域获得应用。”另一方面，孟山都技术战略及开发负责人David Fischhoff说:“TwistDx公司的RPA技术使我们在生物技术产品准确、快速检测方面的能力得以提高。这种测试能加强我们的产品开发和支持能力，尽快的得到准确结果，从而帮助农民提高产量。”

TwistDx’s mission is to become the world leader in the development and sale of mobile and point-of-use diagnostics.

The company owns a substantial portfolio of intellectual property covering all aspects of the Recombinase Polymerase Amplification (RPA) technology, which it is using to develop a growing range of innovative, market-leading products in the fields of:

Medical Diagnostics
Food Testing
Animal Health
Agriculture
Environmental Testing
Biodefence
Scientific Research
TwistDx Inc was founded in 1999 by molecular biologist and protein biochemist, Dr Niall Armes, together with Dr Derek Stemple and Dr Nagesh Mahanthappa with it’s headquarters in Cambridge, Massachusetts, USA and TwistDx Limited, formed in 2002, it’s operational facilities in Cambridge, UK.